TY - JOUR T1 - Reliability of Spike Gene Target Failure for ascertaining SARS-CoV-2 lineage B.1.1.7 prevalence in a hospital setting JF - medRxiv DO - 10.1101/2021.04.12.21255084 SP - 2021.04.12.21255084 AU - José Afonso Guerra-Assunção AU - Paul A. Randell AU - Florencia A. T. Boshier AU - Michael A. Crone AU - Juanita Pang AU - Tabitha Mahungu AU - Paul S. Freemont AU - Judith Breuer Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/14/2021.04.12.21255084.abstract N2 - The appearance of the SARS-CoV-2 lineage B.1.1.7 in the UK in late 2020, associated with faster transmission, sparked the need to find effective ways to monitor its spread. The set of mutations that characterise this lineage include a deletion in position 69 and 70 of the spike protein, which is known to be associated with Spike Gene Target Failure (SGTF) in a commonly used three gene diagnostic qPCR assay. The lower cost and faster turnaround times compared to whole genome sequencing make the use of qPCR for monitoring of the variant spread an attractive proposition. However, there are several potential issues with this approach. Here we use 826 SARS-CoV-2 samples collected in a hospital setting as part of the Hospital Onset COVID Infection (HOCI) study where qPCR was used for viral detection, followed by whole genome sequencing (WGS), to identify the factors to consider when using SGTF to infer lineage B.1.1.7 prevalence in a hospital setting, with potential implications for locations where this variant has recently been introduced.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCOG-UK HOCI is part of COG-UK. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research project has been approved (as a sub-study within the COG-UK HOCI clinical study protocol v5.0) by the National Research Ethics Service Committee (Cambridge South 20/EE/0118).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data was deposited when generated to the appropriate SARS-CoV-2 public repositories (COG-UK and GISAID) and is publicly available. ER -